首页BHC • NYSE
Valeant製藥國際公司
$7.60
1月13日, GMT-5 13:12:37 · USD · NYSE · 免责声明
股票在美国上市的证券总部位于CA
昨日收盘价
$7.89
当日价格范围
$7.45 - $7.80
年度波幅
$3.96 - $11.46
市值
27.50亿 USD
平均交易量
126.70万
市盈率
-
股息率
-
CDP 气候变化得分
D
财务信息
损益表
收入
净收入
(USD)2024年9月年同比变化
收入
25.10亿12.15%
经营支出
12.70亿13.29%
净收入
-8500.00万77.51%
净利润率
-3.3979.93%
每股收益
1.129.34%
息税折旧摊销前利润
8.66亿8.93%
有效税率
-338.10%
总资产
负债总额
(USD)2024年9月年同比变化
现金及短期投资
7.19亿-5.39%
总资产
265.40亿-1.94%
负债总额
267.82亿-1.89%
权益总额
-2.42亿
发行在外的股份
3.68亿
市净率
-2.47
资产回报率
5.13%
资本回报率
6.37%
现金净变动
(USD)2024年9月年同比变化
净收入
-8500.00万77.51%
来自运营的现金
4.05亿43.62%
投资现金
-1.02亿94.60%
融资现金
-1.89亿-110.41%
现金净变动
1.27亿-33.85%
自由现金流
6.07亿261.43%
简介
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell. Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada. Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
成立时间
1959
员工数量
20,270
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单